[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"PersonGen BioTherapeutics (Suzhou) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":276},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,40,63,88,109,128,149,166,188,212,234,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100640207","phase-1-single-arm-open-label-dose-escalating-phase-i-clinical-study-of-pa3-17-injection-in-children-and-adolescents-with-relapsedrefractory-t-lymphoblastic-leukemialymphoma-100640207",false,"NCT07623681","Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed\u002FRefractory T-lymphoblastic Leukemia\u002FLymphoma","R\u002FR T-ALL\u002FLBL","Inclusion Criteria:\n\n* (1) Aged from 3 to 18 years (inclusive), with no restriction on gender. (2) Expected survival time ≥ 3 months. (3) At screening, Karnofsky Performance Status score (for subjects aged ≥ 16 years) or Lansky Performance Score (for subjects aged \\\u003C 16 years) \\> 60 points (see Appendix 4).\n\n  (4) Diagnosed with T-ALL or T-LBL (including ETP-ALL and ETP-LBL) by local laboratories based on the classification criteria of WHO Classification of Haematolymphoid Tumours, 5th Edition: Lymphoid Neoplasms, confirmed via MICM classification (morphology, immunology, cytogenetics and molecular genetics), and\u002For pathological and imaging examinations.\n\nFor subjects diagnosed with T-LBL: bone marrow smear shows blasts between 5% (inclusive) and 20% (exclusive), or focal infiltration is observed on bone marrow biopsy indicating bone marrow involvement of T-LBL.\n\n(5) Subjects with relapsed or refractory disease after failure of standard treatment or without available effective treatment options:\n\n① Refractory disease: Failure to achieve remission after completion of at least 2 cycles of standard induction chemotherapy\\*.\n\n② Relapsed disease: New extramedullary lesions or bone marrow recurrence occurring in subjects who have achieved complete remission (CR).\n\nEarly relapse (\\\u003C 12 months) after complete remission; Late relapse (≥ 12 months) after complete remission with no response to one cycle of standard induction chemotherapy\\*.\n\nDefinition of bone marrow recurrence: If the percentage of blasts\u002Fimmature lymphocytes in bone marrow smear is ≥ 5% and \\\u003C 20%, evidence of molecular recurrence is required. In the absence of molecular recurrence evidence, at least two consecutive test results (both ≥ 5%) are required.\n\n* Failure to achieve remission after treatment with two or more lines of chemotherapy regimens\\*.\n\n  * Two or more episodes of relapse.\n\n    * Relapse after hematopoietic stem cell transplantation. \\* Remission criteria: CR and CRi for T-ALL; CR and PR for T-LBL. (6) At screening: ① Abnormal tumor cells are detected in bone marrow and\u002For peripheral blood by multi-color flow cytometry, regardless of the presence or absence of extramedullary lesions on imaging. Abnormal tumor cells in bone marrow must be CD7-positive; abnormal tumor cells in peripheral blood must be CD7-positive, CD4-negative and CD8-negative.\n\n      * No abnormal tumor cells are detected in bone marrow and\u002For peripheral blood by multi-color flow cytometry, and imaging shows only extramedullary lesions (e.g. lymphadenopathy). Immunohistochemistry of lesion specimens must confirm CD7 positivity with a CD7 positive rate ≥ 70%.\n\n        (7) For subjects with only extramedullary lesions: lesions shall be evaluable (by PET-CT) or measurable (by contrast-enhanced CT) per the 2014 Lugano Criteria for efficacy assessment specified in Appendix 5.\n\n        (8) Liver, renal, cardiac and pulmonary function shall meet the following criteria:\n\n        ① Total bilirubin ≤ 2 × ULN; ALT and AST ≤ 2.5 × ULN. If ALT\u002FAST elevation is judged by the investigator to be caused by the underlying disease (e.g. liver infiltration or biliary obstruction), the upper limit may be extended to ≤ 5 × ULN. For subjects diagnosed with Gilbert's syndrome, total bilirubin ≤ 3.0 × ULN with direct bilirubin ≤ 1.5 × ULN.\n      * Creatinine ≤ 1.5 × ULN.\n* Left ventricular ejection fraction (LVEF) ≥ 45%. ④ Oxygen saturation \\> 91%. (9) The subject and\u002For legal guardian fully understands this trial, has signed the informed consent form, and is willing and able to comply with scheduled visits, treatment regimens, laboratory tests and all other study requirements specified in the study schedule.\n\nExclusion Criteria:\n\n* (1) Patients judged by the investigator to require long-term use of immunosuppressants at screening.\n\n  (2) Cerebrovascular accident or seizure occurring within 6 months prior to signing the informed consent form.\n\n  (3) Uncontrolled graft-versus-host disease (GvHD) or ongoing requirement for systemic treatment for GvHD.\n\n  (4) History of other malignancies (other than T-ALL\u002FLBL) within 5 years prior to screening, except for cured carcinoma in situ.\n\n  (5) Subjects with positive hepatitis B surface antigen (HBsAg) and abnormal peripheral blood hepatitis B virus (HBV) DNA titer; positive hepatitis B core antibody (HBcAb) with abnormal peripheral blood HBV DNA titer; positive hepatitis C virus (HCV) antibody coupled with positive peripheral blood HCV RNA; positive human immunodeficiency virus (HIV) antibody; positive cytomegalovirus (CMV) DNA; positive syphilis serology; positive Epstein-Barr virus (EBV) DNA.\n\n  (6) Severe cardiac diseases, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \\[NYHA\\] Class ≥ III), and severe arrhythmia.\n\n  (7) Unstable systemic diseases as assessed by the investigator, including but not limited to severe hepatic, renal or metabolic diseases requiring medical treatment.\n\n  (8) Presence of chronic progressive neurological diseases. (9) Patients with unresolved acute toxicities from prior treatments. (10) Active or uncontrolled infections requiring systemic therapy (excluding mild genitourinary tract infections and upper respiratory tract infections).\n\n  (11) Female subjects of childbearing potential who plan to become pregnant within 2 years after cell infusion; male subjects whose partners plan to become pregnant within 2 years after cell infusion.\n\n  (12) Subjects who have received CAR-T therapy or other genetically modified cell therapies prior to screening.\n\n  (13) Participation in another clinical trial within 1 month prior to screening (calculated from the last administration of unapproved investigational products).\n\n  (14) Evidence of central nervous system (CNS) involvement identified at screening.\n\n  (15) Any other conditions deemed ineligible for enrollment by the investigator.","ALL","3 Years","18 Years",{"count":5,"type":20},"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed\u002Frefractory T-lymphoblastic leukemia\u002Flymphoma, and determine the recommended phase II dose of PA3-17 injection for this patient population.\n\nSecondary objectives include evaluating the pharmacokinetics\u002Fpharmacodynamics, preliminarily assessing clinical efficacy, and evaluating the immunogenicity of the injection.",[26],"CD7+ T-ALL\u002FLBL","NOT_YET_RECRUITING","2026-05-28",{"date":30,"type":31},"2026-06-03","ACTUAL",{"date":33,"type":20},"2026-06-10",{"date":35,"type":20},"2028-07-30",{"name":37,"class":38},"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100618975","early-phase-1-clinical-study-of-utaa07-injection-in-the-treatment-of-hematologic-and-lymphatic-systemic-malignancies-100618975","NCT07338604","Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies","Clinical Study of UTAA07 Injection in the Treatment of CD7 Positive Adult Relapsed\u002FRefractory Hematologic and Lymphatic Systemic Malignancies","Inclusion Criteria:\n\n* Aged ≥ 18 years, regardless of gender.\n* Expected survival time ≥ 3 months.\n* ECOG performance status score of 0-1.\n* Confirmed diagnosis of relapsed\u002Frefractory CD7-positive hematolymphoid malignancies at screening.\n* Coagulation function, liver and kidney function, and cardiopulmonary function meeting the requirements.\n* Ability to understand the trial and signed informed consent form.\n\nExclusion Criteria:\n\n* A history of malignant tumors other than hematolymphoid malignancies within 5 years prior to screening, excluding carcinoma in situ.\n* Positive results for virological tests or syphilis.\n* Severe cardiac diseases.\n* Unstable systemic diseases as determined by the investigator.\n* Active or uncontrolled infections requiring systemic treatment within 7 days prior to screening, excluding mild urinary and reproductive system infections and upper respiratory tract infections.\n* Pregnant or lactating women; female subjects planning to become pregnant within 2 years after cell infusion; or male subjects whose partners plan to become pregnant within 2 years after the subject's cell infusion.\n* Subjects receiving systemic corticosteroid therapy within 7 days prior to screening, or those judged by the investigator to require long-term systemic corticosteroid therapy during the trial period, excluding inhaled or topical administration.\n* Participation in other clinical studies within 1 month prior to screening.\n* Evidence of central nervous system (CNS) involvement at screening, such as detection of tumor cells in cerebrospinal fluid (CSF) or imaging findings suggestive of CNS infiltration.\n* Patients requiring long-term use of immunosuppressants as determined by the investigator at screening.\n* A history of epilepsy or other central nervous system diseases.\n* Patients with primary immunodeficiency diseases.\n* Other circumstances deemed inappropriate for enrollment by the investigator.",{"count":48,"type":20},15,[50],"EARLY_PHASE1","This is a single-arm, open-label study designed to evaluate the safety, tolerability and cellular pharmacokinetic profiles of UTAA07 Injection. It also aims to preliminarily assess the efficacy of the investigational drug in subjects with relapsed\u002Frefractory hematolymphoid malignancies, so as to identify the optimal dose for subsequent formal clinical trials.",[53],"Hematolymphoid Malignancies","RECRUITING","2026-01-03",{"date":57,"type":31},"2026-01-14",{"date":59,"type":31},"2025-12-12",{"date":61,"type":20},"2027-12-31",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":39},"100616977","early-phase-1-clinical-study-of-lv009-injection-for-the-treatment-of-relapsedrefractory-cd19-positive-hematologic-and-lymphoid-malignancies-100616977","NCT07312630","Clinical Study of LV009 Injection for the Treatment of Relapsed\u002FRefractory CD19-Positive Hematologic and Lymphoid Malignancies","Inclusion Criteria:\n\n* Age 18 to 70 years old (inclusive of both age limits), no gender restrictions, no racial restrictions\n* Expected survival time exceeds 12 weeks\n* ECOG performance status 0-2\n* Meets the NCCN guidelines' criteria for recurrence\u002Frefractory disease and is diagnosed with CD19-positive hematologic malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)\n* Liver and kidney function, as well as cardiopulmonary function, meet requirements.\n* Absolute lymphocyte count ≥ 0.5 × 10⁹\u002FL; platelet count ≥ 50 × 10⁹\u002FL; CD3-positive T cells ≥ 150 cells\u002FμL.\n* Subjects must have a body temperature ≤ 38°C (excluding tumor fever) within 24 hours prior to study drug infusion and must not have significant active infection.\n* Within 5 days prior to the study drug infusion, subjects must not receive therapeutic doses of corticosteroids (\\>5 mg\u002Fday of prednisone or other equivalent doses of corticosteroids) or other immunosuppressive agents.\n\nExclusion Criteria:\n\n* Patients deemed by the investigator to require long-term use of immunosuppressive agents during screening should be excluded.\n* Patients who have experienced a cerebrovascular accident or seizure within the six months prior to signing the informed consent form must be excluded.\n* Patients with malignant tumors other than the study disease must be excluded (only patients with carcinoma in situ may be considered for inclusion).\n* Hepatitis B surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive with peripheral blood hepatitis B virus (HBV) DNA titer outside normal reference range; Hepatitis C virus (HCV) antibody positive with peripheral blood hepatitis C virus (HCV) RNA positive; Human Immunodeficiency Virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Syphilis positive. (Patients meeting any criterion in this section must be excluded.)\n* Patients with severe cardiac conditions must be excluded, including but not limited to: unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \\[NYHA\\] class ≥ III), and severe arrhythmias.\n* Patients judged by the investigator to have unstable systemic diseases must be excluded, including but not limited to those with severe liver, kidney, or metabolic diseases requiring medication.\n* Patients with chronic progressive neurological diseases should be excluded.\n* Patients who have not recovered from acute toxic effects following prior treatment must be excluded.\n* Patients with active infections requiring systemic treatment or uncontrolled infections should be excluded (patients with mild urogenital tract infections and upper respiratory tract infections may be considered for inclusion).","70 Years",{"count":71,"type":20},19,[50],"Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed\u002Frefractory CD19-positive hematologic malignancies.",[75,76],"Non-Hodgkin Lymphoma (NHL)","Acute Lymphoblastic Leukemia (ALL), Adult",[78,79],"CD19","CAR-T","2025-12-16",{"date":82,"type":31},"2025-12-31",{"date":84,"type":31},"2025-09-25",{"date":86,"type":20},"2027-12-12",{"name":37,"class":38},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":48},"100607442","phase-2-pa3-17-injection-in-adult-patients-with-cd7-positive-relapsedrefractory-t-lymphoblastic-leukemialymphoma-100607442","NCT07188610","PA3-17 Injection in Adult Patients With CD7-positive Relapsed\u002FRefractory T-lymphoblastic Leukemia\u002FLymphoma","PA3-17 Injection for the Treatment of Subjects With Relapsed\u002FRefractory T-Lymphoblastic Leukemia\u002FLymphoma: A Single-Arm, Open-Label Phase II Clinical Trial","Inclusion Criteria:\n\n1. Age and Gender: ≥18 years old (inclusive), regardless of gender.\n2. Survival Expectancy: ≥3 months.\n3. Performance Status: ECOG score 0-1.\n4. Diagnosis: Confirmed acute T-cell lymphoblastic leukemia\u002Flymphoma (T-ALL\u002FLBL) according to the WHO fifth edition of the \"Classification of Hematopoietic and Lymphoid Tumors,\" including early T-cell precursor (ETP).\n5. Recurrent or Refractory Disease: Subjects with recurrent\u002Frefractory T-ALL\u002FLBL (including ETP-ALL\u002FLBL).\n6. Screening: Abnormal cells CD7 expression positive.\n7. Lesion Assessment: If the subject has only extramedullary lesions, they must have evaluable lesions.\n8. Meet the requirements of liver, kidney, heart, and lung functions.\n9. No Severe Mental Disorders.\n10. Informed Consent: Ability to understand the trial and signed informed consent form.\n\nExclusion Criteria:\n\n1. Known to have active or uncontrolled autoimmune diseases;\n2. Presence of GvHD;\n3. History of malignant tumors other than T-ALL\u002FLBL within the past 5 years, except for adequately treated cervical intraepithelial neoplasia, basal cell or squamous cell skin cancer, locally treated prostate cancer, and ductal carcinoma in situ of the breast after radical surgery;\n4. Positive test results for hepatitis B, hepatitis C, syphilis, etc.;\n5. Severe heart disease;\n6. Unstable systemic diseases as judged by the investigator;\n7. Presence of active infection or uncontrollable infection requiring systemic treatment;\n8. Pregnant or breastfeeding women, and female subjects planning to conceive within 2 years after cell infusion, or male subjects whose partners plan to conceive within 2 years after cell infusion;\n9. Subjects who have received CAR-T therapy or other gene-modified cell therapy before screening;\n10. Participation in other clinical studies within 1 month before screening (end date of the last application of unapproved innovative drugs);\n11. Evidence of central nervous system involvement at the time of subject screening;\n12. Situations judged by the investigator as not suitable for cell preparation;\n13. Other circumstances deemed unsuitable for enrollment by the investigator.",{"count":96,"type":20},100,[98],"PHASE2","\\*\\*Translation:\\*\\*\n\nThis clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells. Following lymphodepletion pretreatment, a single infusion of PA3-17 injection will be administered. Blood samples will be collected from the subjects before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations. In addition to the baseline period, the treatment phase will involve efficacy assessments at 4 weeks, 2 months, 3 months, and every 3 months thereafter, up to 24 months post-cell infusion. Tumor assessments will continue until disease progression (PD), initiation of new antitumor treatment, death, unacceptable toxicity, investigator decision, or subject's voluntary withdrawal, whichever occurs first.",[101],"CD7-positive Relapsed\u002FRefractory T Lymphoblastic Leukemia\u002FLymphoma","2025-12-04",{"date":104,"type":31},"2025-12-05",{"date":84,"type":31},{"date":107,"type":20},"2027-10-01",{"name":37,"class":38},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":67,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":69,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":39},"100614848","phase-1-clinical-study-of-lv009-injection-for-the-treatment-of-hematologic-and-lymphoid-malignancies-100614848","NCT07284927","Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies","Inclusion Criteria:\n\n1. Aged 18 to 70 years (inclusive), irrespective of sex and race.\n2. Life expectancy greater than 12 weeks.\n3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 2.\n4. Meets the National Comprehensive Cancer Network (NCCN) criteria for relapsed or refractory disease, with a confirmed diagnosis of CD19-positive hematolymphoid malignancy\n5. Adequate hepatic, renal, and cardiopulmonary function\n6. Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹\u002FL; Platelet count ≥ 50 × 10⁹\u002FL; CD3-positive T-cell count ≥ 150 cells\u002FμL\n\nExclusion Criteria:\n\n1. Patients who, in the investigator's judgment at screening, require long-term use of immunosuppressive agents.\n2. History of cerebrovascular accident or convulsive seizures within 6 months prior to signing the informed consent form.\n3. Presence of other active malignant diseases besides the disease under study, with the exception of carcinoma in situ.\n4. Patients with severe cardiac disease, unstable systemic diseases, or chronic progressive neurological disorders, etc.\n5. Patients who have received CAR-T therapy or other genetically modified cell therapies prior to screening.\n6. Patients who have participated in other clinical studies within 1 month prior to screening.\n7. Evidence of central nervous system involvement at the time of screening.",{"count":116,"type":20},10,[23],"This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed\u002Frefractory CD19-positive hematolymphoid malignancies.",[120,121],"Non-Hodgkin Lymphoma","Acute Lymphoblastic Leukemia","2025-12-03",{"date":80,"type":31},{"date":122,"type":31},{"date":126,"type":20},"2027-12-03",{"name":37,"class":38},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":39},"100591601","early-phase-1-clinical-study-on-the-treatment-of-refractory-rheumatoid-arthritis-with-utaa91-injection-100591601","NCT06982547","Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection","Clinical Study on the Treatment of Refractory Moderate - to - Severe Active Rheumatoid Arthritis With UTAA91 Injection","Inclusion Criteria:\n\n* Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.\n* Expected survival time of at least 3 months.\n* Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options.\n* Meet the requirements for liver and kidney function, as well as cardiopulmonary function.\n* Free from severe psychiatric disorders.\n* Able to understand the trial and have signed the informed consent form.\n\nExclusion Criteria:\n\n* A history of malignant tumors other than relapsed\u002Frefractory autoimmune diseases (R\u002FR AID) within 5 years prior to screening.\n* Subjects with positive results in virus\u002Fsyphilis tests.\n* Severe cardiac diseases or unstable systemic diseases.\n* Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening.\n* Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.\n* Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening.\n* Subjects who participated in other clinical studies within 1 month before screening.\n* Other conditions deemed unsuitable for enrollment by the investigator.",{"count":136,"type":20},24,[50],"This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.",[140],"Rheumatoid Arthritis (RA)","2025-05-13",{"date":143,"type":31},"2025-05-21",{"date":145,"type":20},"2025-06",{"date":147,"type":20},"2040-06",{"name":37,"class":38},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":39},"100591600","early-phase-1-clinical-study-on-the-treatment-of-systemic-sclerosis-with-utaa91-injection-100591600","NCT06982534","Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.","Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection","Inclusion Criteria:\n\n* Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.\n* Expected survival time of ≥3 months.\n* Refractory moderate - to - severe active systemic sclerosis that has failed standard treatment or lacks effective therapeutic options.\n* Meets the requirements for liver and kidney function, as well as cardiopulmonary function.\n* Free from severe psychiatric disorders.\n* Able to understand the trial and has signed the informed consent form.\n\nExclusion Criteria:\n\n* A history of malignant tumors other than relapsed\u002Frefractory autoimmune diseases (R\u002FR AID) within 5 years prior to screening.\n* Positive results in virology\u002Fsyphilis tests.\n* Severe cardiac diseases or unstable systemic diseases.\n* Presence of active or uncontrollable infections requiring systemic treatment, or evidence of central nervous system invasion.\n* Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.\n* Subjects who have received CAR - T therapy or other gene - modified cell therapies prior to screening.\n* Subjects who participated in other clinical studies within 1 month prior to screening.\n* Other conditions deemed unsuitable for enrollment by the investigator.",{"count":136,"type":20},[50],"This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.",[160],"Systemic Sclerosis (SSc)",{"date":143,"type":31},{"date":145,"type":20},{"date":164,"type":20},"2040-01",{"name":37,"class":38},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":39},"100523163","early-phase-1-utaa09-injection-in-the-treatment-of-relapsedrefractory-hematolymphatic-malignancies-100523163","NCT06092047","UTAA09 Injection in the Treatment of Relapsed\u002FRefractory Hematolymphatic Malignancies.","Clinical Study of Universal Off-the-shelf Cell Products in Patients With CD19-positive Relapsed\u002FRefractory B-cell Hematolymphatic Malignancies.","Inclusion Criteria:\n\n1. Patients aged between 3\\~70 (including cut-off values), regardless of gender and race;\n2. Expected survival time\\>12 weeks;\n3. ECOG score 0-2;\n4. CD19-positive relapsed\u002Frefractory B-cell hematolymphatic malignancies;\n5. Liver and kidney function, cardiopulmonary function meet the following requirements:\n\n   1. Creatinine ≤ 1.5 ULN;\n   2. Left ventricular ejection fraction ≥ 45%;\n   3. blood oxygen saturation\\>91%;\n   4. Total bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 2.5 × ULN;\n6. Be able to understand the trial and have signed the informed consent.\n\nExclusion Criteria:\n\n1. Those with graft-versus-host disease (GVHD) or requiring long-term systemic immunosuppressants;\n2. Malignant tumors other than CD19-positive hematologic malignancies within 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, and breast ductal carcinoma in situ after radical resection;\n3. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer outside the normal reference range; Those who are positive for hepatitis C virus (HCV) antibodies and positive for hepatitis C virus (HCV) RNA in peripheral blood; Human immunodeficiency virus (HIV) antibody positive person; Positive for cytomegalovirus (CMV) DNA testing; those who test positive for syphilis;\n4. Serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ III), and serious arrhythmia;\n5. Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;\n6. Within 7 days before screening, there is active infection or uncontrollable infection requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);\n7. Pregnant or lactating women, female subjects who planned to conceive within 1 year of cell infusion or male subjects whose partner planned pregnancy within 1 year of their cell infusion;\n8. Screening participants (except for inhalation or local use) who were receiving systemic steroid treatment within 7 days before screening or who were judged by the investigator to require long-term systemic steroid therapy during treatment;\n9. Participated in other clinical studies within 3 month before screening;\n10. There was evidence of central nervous system involvement at participant screening;\n11. Conditions that the investigators considered unsuitable for enrollment.",{"count":116,"type":20},[50],"This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.",[177],"CD19-positive Relapsed or Refractory B-cell Malignancies",[179,180],"CD19 target","UCAR-T",{"date":182,"type":31},"2025-05-16",{"date":184,"type":31},"2023-10-01",{"date":186,"type":20},"2028-04",{"name":37,"class":38},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":39},"100590709","early-phase-1-early-clinical-study-of-utaa91-injection-for-the-treatment-of-relapsedrefractory-autoimmune-diseases-100590709","NCT06970951","Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases","A Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study for Relapsed\u002FRefractory (R\u002FR) Autoimmune Diseases","Inclusion Criteria\n\n1. Age ≥ 18 years (including the cut - off value), with no restrictions on gender.\n2. Expected survival time ≥ 3 months.\n3. Subjects with relapsed\u002Frefractory autoimmune diseases who have failed standard treatment or lack effective treatment options, including but not limited to rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, idiopathic inflammatory myopathies, Sjögren's syndrome, connective tissue disease - related interstitial lung disease, immune thrombocytopenia, primary biliary cholangitis, etc.\n4. Liver and kidney functions and cardiopulmonary functions meet the requirements.\n5. No severe mental disorders.\n6. Able to understand this trial and have signed the informed consent form.\n\nExclusion Criteria\n\n1. Malignant tumors other than relapsed\u002Frefractory autoimmune diseases (R\u002FR AID) within 5 years before screening.\n2. Subjects with positive virus and\u002For syphilis tests.\n3. Presence of severe heart disease or unstable systemic diseases.\n\n5\\. Presence of active or uncontrollable infections requiring systemic treatment.\n\n6\\. Pregnant or breastfeeding women, as well as female subjects who plan to become pregnant within 2 years after cell infusion or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.\n\n7\\. Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening.",{"count":48,"type":20},[50],"This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed\u002Frefractory autoimmune inflammatory diseases (AID).",[199,200,201,202,203],"Systemic Lupus Erythematosus","Rheumatoid Arthritis","Dry Syndrome","Idiopathic Inflammatory Myopathies","Systemic Sclerosis","2025-05-06",{"date":206,"type":31},"2025-05-14",{"date":208,"type":20},"2025-05-18",{"date":210,"type":20},"2027-04-30",{"name":37,"class":38},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":69,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":39},"100583078","clinical-study-of-cd7-car-t-cells-for-relapsedrefractory-autoimmune-diseases-100583078","NCT06871644","Clinical Study of CD7 CAR-T Cells for Relapsed\u002Frefractory Autoimmune Diseases","CD7CAR-T Cell Therapy As a Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study","Inclusion Criteria:\n\n\\- Diagnosed relapsing\u002Frefractory systemic sclerosis that has failed treatment with at least two immunosuppressive and\u002For biologic agents.\n\nBone marrow and coagulation function, liver and kidney function, cardiopulmonary function are satisfied No serious mental disorders\n\nExclusion Criteria:\n\n\\- Malignancy other than AID disease within 5 years prior to screening Hepatitis B surface antigen (HBsAg) positive, AIDS, syphilis and other virus positive persons Severe heart disease",{"count":220,"type":20},18,[222],"NA","The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed\u002Frefractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.",[225],"Systemic Sclerosis - 2013 ACR\u002FEULAR Classification Criteria","2025-03-11",{"date":228,"type":31},"2025-03-12",{"date":230,"type":20},"2025-03-18",{"date":232,"type":20},"2027-03-31",{"name":37,"class":38},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":39},"100537530","utaa17-injection-in-the-treatment-of-relapsedrefractory-multiple-myeloma-100537530","NCT06279026","UTAA17 Injection in the Treatment of Relapsed\u002FRefractory Multiple Myeloma","Single-arm, Open-label, Early-stage Clinical Study of UTAA17 Injection in the Treatment of Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* All subjects or legal representatives must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process.\n* ≥18 years old, regardless of gender, diagnosed with relapsed or refractory multiple myeloma according to the Efficacy Evaluation Criteria for multiple myeloma (IMWG), where relapsed or refractory is defined as: Multiple myeloma that has failed or relapsed after at least 3 lines of therapy (including proteasome inhibitor and immunomodulator-based chemotherapy regimen) in which induction chemotherapy, stem cell transplantation, and maintenance therapy given consecutively are considered a treatment regimen if no disease progression occurs during treatment.\n* The presence of measurable lesions at the time of screening will be determined according to any of the following criteria:\n\n  1. Monoclonal plasma cells in bone marrow ≥ 10%.\n  2. Serum monoclonal protein (M-protein) level ≥10 g\u002FL.\n  3. Urinary M protein level ≥200 mg\u002F24 hours.\n  4. Light chain multiple myeloma with no measurable lesions in serum or urine: serum immunoglobulin free light chain ≥10 mg\u002FdL and abnormal serum immunoglobulin κb \u002Fγ free light chain ratio.\n  5. There are extramedullary lesions.\n* BCMA expression on the cell membrane is positive by flow cytometry and\u002For immunohistochemistry.\n* Patients were unable to undergo autologous hematopoietic stem cell transplantation or relapsed after autologous hematopoietic stem cell transplantation and were determined by the investigators to require treatment.\n* Patients who have previously received CAR T cell therapy should not be included until at least 3 months after the last CAR T cell infusion and no previously used CAR T cells are detectable in peripheral blood or bone marrow.\n* The ECOG score is 0 or 1.\n* Expected survival ≥12 weeks.\n* Subjects must have appropriate organ function and meet all of the following laboratory test results prior to enrollment\n\n  1. Blood routine: Absolute neutrophil count (ANC) \\>0.75×10\\^9 \u002FL; Absolute lymphocyte count (ALC) ≥0.3×10\\^9 \u002FL; Platelet ≥50×10\\^9 \u002FL; Hemoglobin \\>60 g\u002FL\n  2. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN); Serum total bilirubin ≤1.5×ULN, except patients with Gilbert syndrome (patients with Gilbert syndrome ≤3.0 times the upper limit of normal and direct bilirubin ≤1.5 times the upper limit of normal can be included)\n  3. Renal function: serum creatinine ≤2.5×ULN\n  4. Coagulation function: fibrinogen ≥ 1.0g \u002FL; Activated partial thromboplastin time, activated partial thromboplastin time ≤1.5×ULN, and prothrombin time (PT) ≤1.5×ULN\n  5. Must have a minimum level of lung reserve, blood oxygen saturation \\> 92%\n* Hemodynamically stable and left ventricular ejection fraction (LVEF) ≥ 50% as determined by echocardiography.\n\nExclusion Criteria:\n\n* Patients who were determined by the investigators to require long-term immunosuppressant use during screening.\n* Cerebrovascular accident or convulsive attack occurred within 6 months before signing the informed consent.\n* Other malignancies other than MM, except carcinoma in situ.\n* Hepatitis B surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal reference value range; Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; EBV virus DNA and herpes virus DNA positive test; Syphilis test positive.\n* Serious heart disease: including, but not limited to, unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA classification ≥III), and severe arrhythmia.\n* Unstable systemic disease, as determined by the investigator: including, but not limited to, severe liver, kidney, or metabolic disease requiring medical treatment.\n* There are chronic progressive neurological disorders.\n* Patients who have not yet recovered from the acute toxic effects of prior treatment.\n* Presence of active or uncontrolled infections that require systemic treatment (except for mild genitourinary and upper respiratory tract infections).\n* Female subjects who are capable of becoming pregnant and plan to become pregnant within 2 years after cell transfusion; Or a male subject whose partner plans to become pregnant within 2 years of cell transfusion.\n* The researchers assessed that there were other conditions that were not suitable for inclusion.",{"count":48,"type":20},[222],"The clinical trial was designed as a single-arm, open-label clinical study, with the main purpose of exploring the safety, pharmacokinetics, and best recommended dose (RP2D) of the UTAA17 injection in the treatment of relapsed or refractory multiple myeloma (r\u002Fr MM) subjects, and also the efficacy will be observed. Eligible subjects will accept the infusion of UTAA17 injection after pretreatment, and their blood will be collected before and after infusion for evaluation of pharmacokinetics, immunogenicity and safety. This study plans to evaluate efficacy using the revised Evaluation of Efficacy in multiple myeloma -IMWG criteria (2016), which will be evaluated at 4w, 2m, 3m, 6m, and 6 to 24m (at a frequency of Q3m) after cell reinfusion, in addition to the baseline period. Efficacy evaluation continues until one of the following occurs: subject disease progression (PD), acceptance of a new antitumor therapy, death, occurrence of intolerable toxicity, investigator decision, or patient decision to withdraw.",[245],"Relapsed\u002FRefractory Multiple Myeloma","2024-02-23",{"date":248,"type":31},"2024-02-26",{"date":250,"type":20},"2024-04-01",{"date":252,"type":20},"2027-07-01",{"name":37,"class":38},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":261,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},"100482437","phase-1-taa06-injection-in-the-treatment-of-patients-with-b7-h3-positive-relapsed-refractory-neuroblastoma-100482437","NCT05562024","TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed\u002F Refractory Neuroblastoma","An Open-label, Dose-escalation, and Dose-expansion Phase I Trial of TAA06 Injection in Patients With Relapsed\u002FRefractory Neuroblastoma","Inclusion Criteria:\n\n* Age ≥ 1 year (including cut-off value), gender is not limited\n* Expected survival time ≥ 3 months\n* Karnofsky score (\\> 16 years) or Lansky score (≤ 16 years) \\> 60 points\n* Meet the clinical diagnostic criteria and be diagnosed as recurrent \u002F refractory neuroblastoma. For first-line standard treatment, please refer to the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (Chinese Journal of Pediatric surgery, Volume 36, No. 1, 2015), the guidelines for the diagnosis and treatment of Pediatric Neuroblastoma of 2019 by the Health Commission, and the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (CCCG-NB-2021 Program) (Chinese Journal of Pediatric surgery, Volume 43, No. 7, 2022)\n\n  1. Recurrence is defined as the determination of recurrence after remission after at least first-line standard treatment.\n  2. Refractory is defined as a person who is not in remission after at least 4 cycles of chemotherapy (≥ 2 chemotherapeutic drugs, including alkylating agents and platinum)\n* The tumor tissue samples of the subjects were stained by immunohistochemistry (IHC) to show that the expression intensity of B7-H3 on the surface of tumor cell membranes was 1+ or above, and the proportion of positive staining of tumor cell membranes was ≥1%\n* At least one measurable lesion defined by RECISTv1.1 criteria, and at least one lesion that can be irradiated (except bone marrow)\n* Subjects with lesions only in the bone marrow may also be enrolled (without irradiation)\n* Liver and kidney function, cardiopulmonary function must meet the following requirements:\n\n  1. Total bilirubin ≤ 3 × ULN;ALT and AST ≤ 5 × ULN\n  2. Creatinine≤2 ULN\n  3. Left ventricular ejection fraction ≥ 50%\n  4. Blood oxygen saturation ≥ 92%\n* Patients and\u002For their guardians understand the trial and have signed informed consent\n\nExclusion Criteria:\n\n* Patients who were judged by the investigator to require long-term immunosuppressive therapy at the time of screening\n* Cerebrovascular accident or seizure occurred within 6 months before signing the informed consent\n* Malignant tumors other than neuroblastoma, excluding carcinoma in situ\n* Hepatitis B surface antigen (HBsAg) positive; hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; hepatitis C virus (HCV) antibody positive and peripheral blood type C Hepatitis virus (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive\n* Serious cardiac disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ grade III), severe arrhythmia\n* Unstable systemic disease as judged by the investigator: including but not limited to severe liver, kidney or metabolic disease requiring drug therapy\n* Presence of chronic progressive neurological disease\n* Patients who have not recovered from acute toxic effects of prior treatment\n* Active or uncontrolled infection requiring systemic treatment (except mild urogenital and upper respiratory tract infections)\n* Pregnancy-capable female subjects who plan to become pregnant within 2 years of cell reinfusion; or male subjects whose partners plan to become pregnant within 2 years of cell reinfusion\n* Those who have received CAR-T therapy or other gene-modified cell therapy before screening\n* Participated in other clinical studies within 1 month before screening\n* Subjects screened for evidence of central nervous system involvement\n* For patients with liver metastases, the distribution of liver metastases exceeds 1\u002F2 of the liver\n* According to the judgment of the investigators, it does not meet the situation of cell preparation\n* Other circumstances deemed inappropriate by investigators","1 Year",{"count":136,"type":20},[23],"Phase I clinical trials are designed as open-label, dose-escalation and dose-expansion clinical studies, the main purpose of which is to explore the tolerability, safety, cytokinetic characteristics and RP2D and preliminary observation of the efficacy of the study drug in subjects with B7-H3-positive relapsed\u002Frefractory neuroblastoma.",[266],"B7-H3-positive Relapsed\u002F Refractory Neuroblastoma","2023-02-23",{"date":269,"type":31},"2023-02-27",{"date":271,"type":31},"2022-12-30",{"date":273,"type":20},"2039-02-18",{"name":37,"class":38},2,""]